2024
The role of C4d and donor specific antibodies in face and hand transplantation—a systematic review
Huelsboemer L, Moscarelli J, Dony A, Boroumand S, Kochen A, Knoedler L, Yu C, Hauc S, Stögner V, Formica R, Lian C, Murphy G, Pomahac B, Kauke-Navarro M. The role of C4d and donor specific antibodies in face and hand transplantation—a systematic review. Frontiers In Transplantation 2024, 3: 1442006. PMID: 39291278, PMCID: PMC11405992, DOI: 10.3389/frtra.2024.1442006.Peer-Reviewed Original ResearchDonor-specific antibodiesSerum donor-specific antibodiesAntibody-mediated rejectionHigher rejection gradesVascularized composite allotransplantationC4d depositionRejection gradeCellular rejectionRejection episodesSpecific antibodiesDonor-specific antibody statusManagement of antibody-mediated rejectionFace transplantationAcute cellular rejectionAcute rejection episodesAssociated with high gradeTime of biopsyAntibody mediated rejectionFisher's exact testMann-Whitney U testSystematic review of electronic databasesMechanisms of rejectionSystematic reviewReview of electronic databasesC4d staining
2020
Defining chronic rejection in vascularized composite allotransplantation—The American Society of Reconstructive Transplantation and International Society of Vascularized Composite Allotransplantation chronic rejection working group: 2018 American Society of Reconstructive Transplantation meeting report and white paper Research goals in defining chronic rejection in vascularized composite allotransplantation
Kaufman C, Kanitakis J, Weissenbacher A, Brandacher G, Mehra M, Amer H, Zelger B, Zelger B, Pomahac B, McDiarmid S, Cendales L, Morelon E. Defining chronic rejection in vascularized composite allotransplantation—The American Society of Reconstructive Transplantation and International Society of Vascularized Composite Allotransplantation chronic rejection working group: 2018 American Society of Reconstructive Transplantation meeting report and white paper Research goals in defining chronic rejection in vascularized composite allotransplantation. SAGE Open Medicine 2020, 8: 2050312120940421. PMID: 32704373, PMCID: PMC7361482, DOI: 10.1177/2050312120940421.Peer-Reviewed Original ResearchChronic rejectionComposite allograftsFunctional declineReconstructive transplantationComposite allotransplantationHistologic evidenceDe novo donor-specific antibodiesAmerican SocietyNovo donor-specific antibodiesNormal allograft functionDonor-specific antibodiesInternational SocietyVascularized Composite AllotransplantationAcute rejectionAllograft functionAllograft recipientsImmunosuppressive therapyTreatment regimensRisk factorsUterine transplantationUpper extremityMeeting reportAllograftsTransplantationClinical cases
2016
Codominant Role of Interferon‐γ– and Interleukin‐17–Producing T Cells During Rejection in Full Facial Transplant Recipients
Borges T, O'Malley J, Wo L, Murakami N, Smith B, Azzi J, Tripathi S, Lane J, Bueno E, Clark R, Tullius S, Chandraker A, Lian C, Murphy G, Strom T, Pomahac B, Najafian N, Riella L. Codominant Role of Interferon‐γ– and Interleukin‐17–Producing T Cells During Rejection in Full Facial Transplant Recipients. American Journal Of Transplantation 2016, 16: 2158-2171. PMID: 26749226, PMCID: PMC4979599, DOI: 10.1111/ajt.13705.Peer-Reviewed Original ResearchConceptsDe novo donor-specific antibody developmentDe novo donor-specific antibodiesInterleukin-17-producing T cellsT helper 2 cell phenotypeFacial transplantationDonor-specific antibody developmentNovo donor-specific antibodiesChemotactic protein-1 levelsPeripheral blood mononuclear cellsAcute cellular rejectionAnti-HLA antibodiesDonor-specific antibodiesFollicular helper cellsImmune cell subsetsProtein-1 levelsBlood mononuclear cellsMedium-term outcomesSkin biopsy specimensFull facial transplantationCellular rejection processLife-changing procedureCellular rejectionCodominant roleDonor alloreactivityTransplant recipients